Medical device CRO Factory brings Boston Biomedical into its fold

Handshake business deal executives
Factory-CRO Group, a medical device and in vitro diagnostics-focused CRO based in the Netherlands, has merged with U.S.-based Boston Biomedical Associates. (Pixabay)

Factory-CRO Group, a medical device and in vitro diagnostics-focused CRO based in the Netherlands, has merged with U.S.-based Boston Biomedical Associates.

Financial terms of the deal weren’t announced.

With the addition of Boston Biomedical, Factory-CRO Group now boasts expanded operations in the U.S., as well as sites in Australia, New Zealand and Europe. Factory-CRO Group said its goal is to become the leading global CRO focused on medical devices and medical technology. 


How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

“This merger allows us to provide our specialized expertise and a continued commitment to the highest level of customized service to a larger audience,” Dirk Meijer, M.D., Ph.D., the company’s chief executive, said in a statement. “We operate from our own offices located within each region housed with employees that have refined expertise to meet our unique client needs.”

A little over a year ago, Factory-CRO Group acquired Milestone Research Organization. Factory-CRO Group offers medical device companies services in data management, consultancy regarding study design and budget and regulatory strategy, regulatory filings, clinical monitoring and reimbursement.

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

PPD, which is going public (again) after years of being private, is ramping up its clinical research units (CRUs).

U.S.-China biotech Brii Biosciences is pushing out into new territory with a new hire alongside a focus on a new R&D area.